Friday moves from sleep to longevity to cognition with emideltide (DSIP), Epitalon, and Semax following a major Day 1 for peptide compounding.
PCAC Day 2 has a clear arc: sleep, longevity, and cognition.
Emideltide (DSIP), Epitalon, and Semax take the stage on July 24 after favorable Day 1 results for BPC-157, KPV, and TB-500.
Emideltide opens with sleep
Emideltide is better known as delta sleep-inducing peptide, or DSIP. FDA reviewed the free-base and acetate forms for chronic insomnia, narcolepsy, and opioid withdrawal.
Read the full DSIP PCAC vote preview.
Epitalon brings the longevity audience
Epitalon is a four-amino-acid peptide with a major following in longevity circles. FDA's PCAC review focuses on insomnia, with separate votes scheduled for Epitalon free base and acetate.
Read the full Epitalon PCAC vote preview.
Semax closes with cognition
Semax brings the neurological side of peptide interest to the committee. FDA reviewed cerebral ischemia, migraine, and trigeminal neuralgia.
Read the full Semax PCAC vote preview.
Day 1 momentum carries into Friday
BPC-157 received two favorable 8–6–1 recommendations. KPV followed with a favorable result. TB-500 added another favorable 8–6–1 vote.
That run gives Day 2 a powerful starting point and puts the Section 503A Bulks List in the national spotlight.
Watch PCAC Day 2
The meeting begins at 8 a.m. Eastern. Watch the official FDA livestream and follow every result on Rebody's PCAC peptide tracker.
PCAC Day 2 FAQ
Which peptides are on PCAC Day 2?
Emideltide (DSIP), Epitalon, and Semax.
When does PCAC Day 2 begin?
The July 24 meeting begins at 8 a.m. Eastern.
Where can I watch PCAC Day 2?
FDA provides a free YouTube livestream linked from Rebody's tracker.